These innovative compounds represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://larissauzar969718.blogpixi.com/39419296/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide